新型自膨胀经心尖主动脉瓣生物瓣的早期临床结果
本研究评估了30例低冠脉高度、重度症状性主动脉瓣狭窄患者使用Acurate TA自膨胀经心尖瓣膜的1年早期结果。器械植入全部成功,30天院内死亡率为3.3%,无冠脉阻塞或卒中,1年生存率89%,瓣膜血流动力学显著改善。
要点
- Acurate TA瓣膜在低冠脉高度患者中植入成功率高,无冠脉阻塞。
- 30天院内死亡率3.3%,1年生存率89%,无卒中发生。
- 术后平均和峰值跨瓣压差显著下降,无中度以上瓣周漏。
核心结论
- Acurate TA瓣膜在冠脉阻塞高危患者中可安全植入,并取得良好的早期和1年结局。
研究设计与样本
- 单中心前瞻性研究,连续纳入30例重度症状性主动脉瓣狭窄患者,年龄85±6岁,女性占63%,STS评分8.4±6.0。
- 患者平均左、右冠脉高度分别为10.8±1.5 mm和16.4±4.1 mm,窦部与瓣环比值为1.3±0.8。
主要发现
- 30例器械植入全部成功,30天院内死亡率为3.3%(n=1),无冠脉阻塞或卒中。
- 1例(3.3%)发生心尖破裂需体外循环修复,1例(3.3%)发生局限性股动脉夹层,1例(3.7%)需要新起搏器。
- 平均跨瓣压差从59±17 mmHg降至14±7 mmHg,峰值跨瓣压差从84±31 mmHg降至28±12 mmHg(P < .0005)。
- 无患者出现超过轻度的瓣周主动脉瓣反流,30天时96.7%(n=29)为NYHA I/II级。
- 30天和1年生存率分别为97%和89%。
临床怎么用
- 对于冠脉高度低、冠脉阻塞风险高的重度主动脉瓣狭窄患者,可考虑使用Acurate TA瓣膜经心尖途径植入。
局限性
- 研究样本量小(30例),为非随机单中心研究,随访时间仅1年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Coronary obstruction remains a challenging complication of transcatheter aortic valve replacement; however, a new self-expanding transapical prosthesis may reduce this risk. The purpose of this study was to evaluate the early 1-year outcomes of patients with low coronary heights who received the Acurate TA bioprosthesis (Symetis, Ecublens, Switzerland). METHODS: Between May 2014 and April 2015, 30 consecutive patients (aged 85 ± 6 years, 63% were female, Society of Thoracic Surgeons score 8.4 ± 6.0) with severe, symptomatic aortic stenosis underwent transcatheter aortic valve replacement with the Acurate TA bioprosthesis. Relevant patient characteristics included reoperation in 47% (n = 14), peripheral vascular disease in 43% (n = 13), and porcelain aorta in 30% (n = 9). The mean left and right coronary heights were 10.8 ± 1.5 mm and 16.4 ± 4.1 mm, respectively, with a sinus of Valsalva : annular ratio of 1.3 ± 0.8. RESULTS: All 30 device implants were successful. The 30-day in-hospital mortality was 3.3% (n = 1), and no patients had coronary obstruction or stroke. One patient (3.3%) had apical rupture requiring cardiopulmonary bypass for repair, 1 patient (3.3%) had a localized femoral artery dissection, and 1 patient (3.7%) required a new pacemaker. There were no other complications. Mean and peak transaortic valve gradients decreased from 59 ± 17 and 84 ± 31 mm Hg to 14 ± 7 and 28 ± 12 mm Hg, respectively (P < .0005). No patients had more than mild paravalvular aortic insufficiency. At 30 days, there were no further complications and 96.7% (n = 29) were in New York Heart Association class I/II. Survival at 30 days and 1 year was 97% and 89%, respectively. CONCLUSIONS: The Symetis Acurate TA device demonstrates high procedural success and excellent acute and 1-year patient outcomes. The device allows safe implantation in patients at higher risk for coronary artery obstruction.
引用
- Chu MW, Bagur R, Losenno KL, et al. Early clinical outcomes of a novel self-expanding transapical transcatheter aortic valve bioprosthesis. J Thorac Cardiovasc Surg. 2016. PMID: 28073571. doi:10.1016/j.jtcvs.2016.11.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。